Madrigal gains full control over Rezdiffra patent term extensions from Roche

MADRIGAL PHARMACEUTICALS, INC.

Madrigal gets exclusive right to manage all patent term extensions for Rezdiffra, including Roche-owned and joint patents.
Royalty reduction on Rezdiffra net sales is deferred until expiration of certain patent term extensions that have been or could be filed.
Amendment modifies the 2008 Research, Development, and Commercialization Agreement with Roche.
Madrigal also obtains full rights over joint patent rights and know-how without consent or accounting to Roche.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MADRIGAL PHARMACEUTICALS, INC. amended First Amendment to the Research, Development, and Commercialization Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) (effective 2026-01-29).

Action: amendment
Agreement: collaboration
Counterparty: F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”)
Effective: 2026-01-29

Exact text from the filing

On January 29, 2026 (the “Effective Date”), Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment (the “Amendment”) to the Research, Development, and Commercialization Agreement dated as of December 18, 2008 between the Company and Roche.

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-008698

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.